Market Overview

UPDATE: Piper Jaffray Cuts PT to $15 on Achillion Pharmaceuticals on Equity Offering Dilution

Share:
Related ACHN
18 Biggest Mid-Day Gainers For Friday
15 Stocks Moving In Friday's Pre-Market Session

Piper Jaffray maintained Achillion Pharmaceuticals (NASDAQ: ACHN) with an Overweight rating and lowered the price target from $16.00 to $15.00.

Piper Jaffray said, "Achillion now holds proforma cash of $211 million following a recent 16.9 million share offering. We are buyers of ACHN shares ahead of SVR-4 data from the 12-week trial of ACH-3102 + ribavarin in 8 HCV genotype 1b patients at EASL in April. … We continue to see Achillion as a likely take-out candidate for its promising HCV pipeline. We reiterate our Overweight rating, however are trimming our price target to $15 from $16 price target due to dilution from the equity offering."

Achillion Pharmaceuticals closed at $8.15 on Friday.

Latest Ratings for ACHN

DateFirmActionFromTo
Sep 2016WedbushInitiates Coverage onOutperform
Sep 2016FBR CapitalInitiates Coverage onOutperform
Jul 2016Chardan CapitalInitiates Coverage onSell

View More Analyst Ratings for ACHN
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings

 

Related Articles (ACHN)

View Comments and Join the Discussion!